[Effect of irisin on hypoxic-ischemic brain damage in neonatal rats].

OBJECTIVE To study the effect and mechanism of action of irisin on hypoxic-ischemic brain damage in neonatal rats. METHODS A total of 248 7-day-old Sprague-Dawley rats were randomly divided into a sham-operation group, a model group, and low- and high-dose irisin intervention groups (n=62 each). The rats in the model and irisin intervention groups were given hypoxic treatment after right common carotid artery ligation to establish a model of hypoxic-ischemic brain damage. Those in the sham-operation group were given the separation of the right common carotid artery without ligation or hypoxic treatment. The rats in the high- and low-dose irisin intervention groups were given intracerebroventricular injection of recombinant irisin polypeptide at a dose of 0.30 µg and 0.15 µg respectively. Those in the model and sham-operation groups were given the injection of an equal volume of PBS. The water maze test was used to compare neurological behaviors between groups. TTC staining, hematoxylin-eosin staining and TUNEL staining were used to observe histopathological changes of the brain. Western blot was used to measure the expression of the apoptosis-related molecules cleaved-caspase-3 (CC3), BCL-2 and BAX. RESULTS Compared with the sham-operation group, the model group had a significant increase in latency time and a significant reduction in the number of platform crossings (P<0.05). Compared with the model group, the high-dose irisin intervention group had a significant reduction in latency time and a significant increase in the number of platform crossings (P<0.05). Compared with the sham-operation group, the model group had massive infarction in the right hemisphere, with significant increases in karyopyknosis and karyorrhexis. Compared with the model group, the high-dose irisin intervention group had a smaller infarct area of the right hemisphere, with reductions in karyopyknosis and karyorrhexis. The model group had a significantly higher apoptosis rate of cells in the right cerebral cortex and the hippocampus than the sham-operation group. The high-dose irisin intervention group had a significantly lower apoptosis rate than the model group (P<0.05). At 24 and 48 hours after modeling, the sham-operation group had a significantly lower level of CC3 than the model group (P<0.05). Compared with the model group, the high-dose irisin intervention group had a significantly lower level of CC3 and a significantly higher BCL-2/BAX ratio (P<0.05). The low-dose irisin intervention group had similar laboratory markers and histopathological changes of the brain to the model group. CONCLUSIONS Irisin can alleviate hypoxic-ischemic brain damage in neonatal rats in a dose-dependent manner, possibly by reducing cell apoptosis in the cerebral cortex and the hippocampus.

[1]  L. Walensky.  Targeting BAX to drug death directly , 2019, Nature Chemical Biology.

[2]  C. Zeng,et al.  Irisin exerts a therapeutic effect against myocardial infarction via promoting angiogenesis , 2019, Acta Pharmacologica Sinica.

[3]  A. Gunn,et al.  Therapeutic Hypothermia in Neonatal Hypoxic-Ischemic Encephalopathy , 2019, Current Neurology and Neuroscience Reports.

[4]  Rongqian Wu,et al.  Irisin alleviates liver ischemia-reperfusion injury by inhibiting excessive mitochondrial fission, promoting mitochondrial biogenesis and decreasing oxidative stress , 2018, Redox biology.

[5]  Li Zhang,et al.  Mesenchymal Stem Cells Protect Against Hypoxia‐Ischemia Brain Damage by Enhancing Autophagy Through Brain Derived Neurotrophic Factor/Mammalin Target of Rapamycin Signaling Pathway , 2018, Stem cells.

[6]  A. Vakili,et al.  Irisin Peptide Protects Brain Against Ischemic Injury Through Reducing Apoptosis and Enhancing BDNF in a Rodent Model of Stroke , 2018, Neurochemical Research.

[7]  Q. Ruan,et al.  Detection and quantitation of irisin in human cerebrospinal fluid by tandem mass spectrometry , 2018, Peptides.

[8]  O. Baud,et al.  Sexually Dimorphic Outcomes after Neonatal Stroke and Hypoxia-Ischemia , 2017, International journal of molecular sciences.

[9]  Y. Li,et al.  Irisin protects mitochondria function during pulmonary ischemia/reperfusion injury , 2017, Science Translational Medicine.

[10]  C. Thornton,et al.  Cell Death in the Developing Brain after Hypoxia-Ischemia , 2017, Front. Cell. Neurosci..

[11]  B. Tatlı,et al.  Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment , 2017, Expert review of neurotherapeutics.

[12]  A. Mathur,et al.  Safety and Short‐Term Outcomes of Therapeutic Hypothermia in Preterm Neonates 34‐35 Weeks Gestational Age with Hypoxic‐Ischemic Encephalopathy , 2017, The Journal of pediatrics.

[13]  A. Malhotra,et al.  Preterm Hypoxic–Ischemic Encephalopathy , 2016, Front. Pediatr..

[14]  C. Thornton,et al.  Role of mitochondria in apoptotic and necroptotic cell death in the developing brain , 2015, Clinica chimica acta; international journal of clinical chemistry.

[15]  H. Ahsan,et al.  The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update , 2015, Archives of Toxicology.

[16]  I. Sahin,et al.  Alterations of irisin concentrations in saliva and serum of obese and normal-weight subjects, before and after 45min of a Turkish bath or running , 2013, Peptides.

[17]  S. Aydin,et al.  Copeptin, adropin and irisin concentrations in breast milk and plasma of healthy women and those with gestational diabetes mellitus , 2013, Peptides.

[18]  E. Gulczyńska,et al.  [Therapeutic hypothermia for neonatal hypoxic-ischemic encephalopathy]. , 2012, Ginekologia polska.

[19]  M. Ruth.  A PGC1–α–dependent myokine that drives brown–fat–like development of white fat and thermogenesis , 2012 .